File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s12933-024-02344-6
- Scopus: eid_2-s2.0-85202742108
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial
Title | Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial |
---|---|
Authors | |
Keywords | Cardiac MRI Diabetes Empagliflozin Left atrial function |
Issue Date | 28-Aug-2024 |
Publisher | BioMed Central |
Citation | Cardiovascular Diabetology, 2024, v. 23, n. 1 How to Cite? |
Abstract | Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated reduction in heart failure outcomes in patients with type 2 diabetes mellitus, although the exact mechanism of benefit remains unclear. Alteration in left atrial (LA) function due to chronic pressure or volume overload is a hallmark of heart failure. Objective: To evaluate the effect of the SGLT2 inhibitor empagliflozin on LA volume and function. Methods: 90 patients with coronary artery disease and type 2 diabetes (T2DM) were randomized to empagliflozin (n = 44) or placebo (n = 46), and underwent cardiac magnetic resonance (CMR) imaging at baseline and after 6 months. The main outcome was change in LA volume; LA function, including active and passive components, was also measured by a blinded reader. Results: At baseline, there was no significant difference in LA volumes between the empagliflozin (indexed maximum LA volume 26.4 ± 8.4mL/m2, minimum LA volume 11.1 ± 5.7mL/m2) and placebo (indexed maximum LA volume 28.7 ± 8.2mL/m2, minimum LA volume 12.6 ± 5.0mL/m2) groups. After 6 months, changes in LA volumes did not differ with adjusted difference (empagliflozin minus placebo): 0.99 mL/m2 (95% CI: -1.7 to 3.7 mL/m2; p = 0.47) for indexed maximum LA volume, and 0.87 mL/m2 (95% CI: -0.9 to 2.6 mL/m2; p = 0.32) for indexed minimum LA volume. Changes in total LA emptying fraction were also similar, with between-group adjusted mean difference - 0.01 (95% CI: -0.05 to 0.03, p = 0.59). Conclusion: SGLT2 inhibition with empagliflozin for 6 months did not have a significant impact on LA volume and function in patients with T2DM and coronary artery disease. (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes [EMPA-HEART]; NCT02998970). |
Persistent Identifier | http://hdl.handle.net/10722/348760 |
ISSN | 2023 Impact Factor: 8.5 2023 SCImago Journal Rankings: 2.621 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pourafkari, Marina | - |
dc.contributor.author | Connelly, Kim A | - |
dc.contributor.author | Verma, Subodh | - |
dc.contributor.author | Mazer, C David | - |
dc.contributor.author | Teoh, Hwee | - |
dc.contributor.author | Quan, Adrian | - |
dc.contributor.author | Goodman, Shaun G | - |
dc.contributor.author | Rai, Archana | - |
dc.contributor.author | Ng, Ming Yen | - |
dc.contributor.author | Deva, Djeven P | - |
dc.contributor.author | Triverio, Piero | - |
dc.contributor.author | Jiminez-Juan, Laura | - |
dc.contributor.author | Yan, Andrew T | - |
dc.contributor.author | Ge, Yin | - |
dc.date.accessioned | 2024-10-15T00:30:39Z | - |
dc.date.available | 2024-10-15T00:30:39Z | - |
dc.date.issued | 2024-08-28 | - |
dc.identifier.citation | Cardiovascular Diabetology, 2024, v. 23, n. 1 | - |
dc.identifier.issn | 1475-2840 | - |
dc.identifier.uri | http://hdl.handle.net/10722/348760 | - |
dc.description.abstract | <p><strong>Background: </strong>Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated reduction in heart failure outcomes in patients with type 2 diabetes mellitus, although the exact mechanism of benefit remains unclear. Alteration in left atrial (LA) function due to chronic pressure or volume overload is a hallmark of heart failure.</p><p><strong>Objective: </strong>To evaluate the effect of the SGLT2 inhibitor empagliflozin on LA volume and function.</p><p><strong>Methods: </strong>90 patients with coronary artery disease and type 2 diabetes (T2DM) were randomized to empagliflozin (n = 44) or placebo (n = 46), and underwent cardiac magnetic resonance (CMR) imaging at baseline and after 6 months. The main outcome was change in LA volume; LA function, including active and passive components, was also measured by a blinded reader.</p><p><strong>Results: </strong>At baseline, there was no significant difference in LA volumes between the empagliflozin (indexed maximum LA volume 26.4 ± 8.4mL/m2, minimum LA volume 11.1 ± 5.7mL/m2) and placebo (indexed maximum LA volume 28.7 ± 8.2mL/m2, minimum LA volume 12.6 ± 5.0mL/m2) groups. After 6 months, changes in LA volumes did not differ with adjusted difference (empagliflozin minus placebo): 0.99 mL/m2 (95% CI: -1.7 to 3.7 mL/m2; p = 0.47) for indexed maximum LA volume, and 0.87 mL/m2 (95% CI: -0.9 to 2.6 mL/m2; p = 0.32) for indexed minimum LA volume. Changes in total LA emptying fraction were also similar, with between-group adjusted mean difference - 0.01 (95% CI: -0.05 to 0.03, p = 0.59).</p><p><strong>Conclusion: </strong>SGLT2 inhibition with empagliflozin for 6 months did not have a significant impact on LA volume and function in patients with T2DM and coronary artery disease. (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes [EMPA-HEART]; <a href="http://clinicaltrials.gov/show/NCT02998970" title="See in ClinicalTrials.gov">NCT02998970</a>).<br></p> | - |
dc.language | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.ispartof | Cardiovascular Diabetology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Cardiac MRI | - |
dc.subject | Diabetes | - |
dc.subject | Empagliflozin | - |
dc.subject | Left atrial function | - |
dc.title | Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s12933-024-02344-6 | - |
dc.identifier.scopus | eid_2-s2.0-85202742108 | - |
dc.identifier.volume | 23 | - |
dc.identifier.issue | 1 | - |
dc.identifier.eissn | 1475-2840 | - |
dc.identifier.issnl | 1475-2840 | - |